Abstract
Background: Efficacy of melatonin in treating sleep disorders has been demonstrated in numerous studies. Being with short half-life, melatonin needs to be formulated in extended-release tablets to prevent the fast drop of its plasma concentration. However, an attempt to mimic melatonin natural plasma levels during night time is challenging.
Methods: In this work, Artificial Neural Networks (ANNs) were used to optimize melatonin release from hydrophilic polymer matrices. Twenty-seven different tablet formulations with different amounts of hydroxypropyl methylcellulose, xanthan gum and Carbopol®974P NF were prepared and subjected to drug release studies. Using dissolution test data as inputs for ANN designed by Visual Basic programming language, the ideal number of neurons in the hidden layer was determined trial and error methodology to guarantee the best performance of constructed ANN.
Results: Results showed that the ANN with nine neurons in the hidden layer had the best results. ANN was examined to check its predictability and then used to determine the best formula that can mimic the release of melatonin from a marketed brand using similarity fit factor.
Conclusion: This work shows the possibility of using ANN to optimize the composition of prolonged-release melatonin tablets having dissolution profile desired.
Keywords: ANN, drug delivery, hydrophilic polymers, melatonin, similarity fit factors, tablet formulation.
Current Drug Delivery
Title:Optimization of Melatonin Dissolution from Extended Release Matrices Using Artificial Neural Networking
Volume: 13 Issue: 4
Author(s): Martarelli D., Casettari L., Shalaby K.S., Soliman M.E., Cespi M., Bonacucina G., Fagioli L., Perinelli D.R., Lam J.K.W. and Palmieri G.F.
Affiliation:
Keywords: ANN, drug delivery, hydrophilic polymers, melatonin, similarity fit factors, tablet formulation.
Abstract: Background: Efficacy of melatonin in treating sleep disorders has been demonstrated in numerous studies. Being with short half-life, melatonin needs to be formulated in extended-release tablets to prevent the fast drop of its plasma concentration. However, an attempt to mimic melatonin natural plasma levels during night time is challenging.
Methods: In this work, Artificial Neural Networks (ANNs) were used to optimize melatonin release from hydrophilic polymer matrices. Twenty-seven different tablet formulations with different amounts of hydroxypropyl methylcellulose, xanthan gum and Carbopol®974P NF were prepared and subjected to drug release studies. Using dissolution test data as inputs for ANN designed by Visual Basic programming language, the ideal number of neurons in the hidden layer was determined trial and error methodology to guarantee the best performance of constructed ANN.
Results: Results showed that the ANN with nine neurons in the hidden layer had the best results. ANN was examined to check its predictability and then used to determine the best formula that can mimic the release of melatonin from a marketed brand using similarity fit factor.
Conclusion: This work shows the possibility of using ANN to optimize the composition of prolonged-release melatonin tablets having dissolution profile desired.
Export Options
About this article
Cite this article as:
D. Martarelli, L. Casettari, K.S. Shalaby, M.E. Soliman, M. Cespi, G. Bonacucina, L. Fagioli, D.R. Perinelli, J.K.W. Lam and G.F. Palmieri, Optimization of Melatonin Dissolution from Extended Release Matrices Using Artificial Neural Networking, Current Drug Delivery 2016; 13 (4) . https://dx.doi.org/10.2174/1567201812666150608101528
DOI https://dx.doi.org/10.2174/1567201812666150608101528 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advancements in Robotic and AI-Based Drug Discovery and Delivery for Neurological Disorders
Neurological disorders, including Alzheimer's disease, Parkinson's disease, epilepsy, and brain tumors, pose significant challenges in drug delivery due to the blood-brain barrier's intricate structure and the complexity of neuronal networks. Traditional drug delivery methods often fall short in reaching therapeutic concentrations within the central nervous system, limiting treatment efficacy and ...read more
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access to both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Patent Selections
Recent Patents on DNA & Gene Sequences Administration of Ethanolic Extract of Ocimum Basilicum Leaves Attenuates Depression like Behavior in the Rats Sensitized by Ovalbumin
Current Nutrition & Food Science Interlocked Systems in Nanomedicine
Current Topics in Medicinal Chemistry Voltage-Gated Sodium Channels in Neurological Disorders
CNS & Neurological Disorders - Drug Targets Human Defensins: Synthesis and Structural Properties
Current Pharmaceutical Design Clear Shot at Primary Aim: Susceptibility of Trypanosoma cruzi Organelles, Structures and Molecular Targets to Drug Treatment
Current Topics in Medicinal Chemistry New Insights into Biological Markers of Frontotemporal Lobar Degeneration Spectrum
Current Medicinal Chemistry Insights into Airway Infections by Enterococci: A Review
Recent Patents on Anti-Infective Drug Discovery Charcot-Marie-Tooth Disease and Related Hereditary Neuropathies: From Gene Function to Associated Phenotypes
Current Molecular Medicine Caffeine; the Forgotten Potential for Parkinson's Disease
CNS & Neurological Disorders - Drug Targets An Overview on the Role of α -Synuclein in Experimental Models of Parkinson’s Disease from Pathogenesis to Therapeutics
CNS & Neurological Disorders - Drug Targets Progressive Supranuclear Palsy: What Do We Know About it?
Current Medicinal Chemistry Genetic Markers of Osteoarthritis
Current Rheumatology Reviews Mechanism of Bioactive Transfer through Liposomal Bilayers
Current Drug Targets Is There A Pulse Wave Encephalopathy Component To Multiple Sclerosis?
Current Neurovascular Research Association of Oxidative Stress to the Genesis of Anxiety: Implications for Possible Therapeutic Interventions
Current Neuropharmacology Meditation: A Review of its Use in Western Medicine and, in Particular, its Role in the Management of Sexual Dysfunction
Current Psychiatry Reviews Withdrawn: Percutaneous Multi-angle Thread Needle for Two- or Three-part Unstable Fractures of the Proximal Humerus in Older Population
Current Medical Imaging Principles and Therapeutic Relevance for Targeting Mitochondria in Aging and Neurodegenerative Diseases
Current Pharmaceutical Design Wnt/β-Catenin Signaling in Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets